ES2070627T3 - Proceso para preparar (-)-((4-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridacinil)fenil)-hidrazono)propanodinitrilo. - Google Patents

Proceso para preparar (-)-((4-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridacinil)fenil)-hidrazono)propanodinitrilo.

Info

Publication number
ES2070627T3
ES2070627T3 ES92901317T ES92901317T ES2070627T3 ES 2070627 T3 ES2070627 T3 ES 2070627T3 ES 92901317 T ES92901317 T ES 92901317T ES 92901317 T ES92901317 T ES 92901317T ES 2070627 T3 ES2070627 T3 ES 2070627T3
Authority
ES
Spain
Prior art keywords
propanodinitrilo
piridacinil
hidrazone
tetrahidro
fenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901317T
Other languages
English (en)
Inventor
Pentti Nore
Erkki Honkanen
Reijo Backstrom
Tom Wikberg
Heimo Haikala
Jorma Haarala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100049A external-priority patent/GB9100049D0/en
Priority claimed from GB919118947A external-priority patent/GB9118947D0/en
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Application granted granted Critical
Publication of ES2070627T3 publication Critical patent/ES2070627T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

ENANTIOMERO CASI OPTICAMENTE PURO DE PROPANO (-) DACINIL) FENIL] HIDRAZONO] O LAS SALES DEL MISMO FARMACEUTICAMENTE ACEPTABLES, MEDIAN EN EL PROCESO PARA LA PREPARACION DESCRITA. EL PRODUCTO ES UTIL COMO AGENTE TONICO CARDIACO, ANTI HIPERTENSIVO Y VASODILATADOR, PARA EL TRATAMIENTO DE LOS ATAQUES DE CORAZON.
ES92901317T 1991-01-03 1992-01-03 Proceso para preparar (-)-((4-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridacinil)fenil)-hidrazono)propanodinitrilo. Expired - Lifetime ES2070627T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100049A GB9100049D0 (en) 1991-01-03 1991-01-03 (-)-6-(4-(dicyanomethylidenehydrazino)phenyl)-4,5-dihydro-5-methylpyridazin-3(2h)one
GB919118947A GB9118947D0 (en) 1991-09-05 1991-09-05 Method for the optical resolution of racemic 6-(4-amino-phenyl)-methyl-pyridazin-3(2h)one and preparation of optically active derivatives thereof

Publications (1)

Publication Number Publication Date
ES2070627T3 true ES2070627T3 (es) 1995-06-01

Family

ID=26298204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901317T Expired - Lifetime ES2070627T3 (es) 1991-01-03 1992-01-03 Proceso para preparar (-)-((4-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridacinil)fenil)-hidrazono)propanodinitrilo.

Country Status (32)

Country Link
US (3) US5424428A (es)
EP (1) EP0565546B1 (es)
JP (2) JP2635445B2 (es)
KR (1) KR100207145B1 (es)
AT (1) ATE119525T1 (es)
AU (1) AU645399B2 (es)
BG (1) BG62002B1 (es)
BR (1) BR1100737A (es)
CA (2) CA2099262C (es)
CY (1) CY1878A (es)
DE (1) DE69201640T2 (es)
DK (1) DK0565546T3 (es)
EE (1) EE02946B1 (es)
ES (1) ES2070627T3 (es)
FI (1) FI105183B (es)
GB (1) GB2251615B (es)
GE (1) GEP19991868B (es)
HK (1) HK117395A (es)
HR (1) HRP921251B1 (es)
HU (1) HU218659B (es)
IE (1) IE72101B1 (es)
IL (2) IL114028A (es)
LU (1) LU90920I2 (es)
LV (1) LV11174B (es)
NO (2) NO300682B1 (es)
NZ (1) NZ241194A (es)
PL (2) PL169415B1 (es)
RO (1) RO111847B1 (es)
RU (1) RU2118317C1 (es)
SI (1) SI9112003A (es)
WO (1) WO1992012135A1 (es)
YU (1) YU48767B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
AU3855995A (en) * 1994-11-11 1996-06-06 Nippon Soda Co., Ltd. Optically active compound
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI981473L (fi) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Menetelmä pulmonaalihypertension hoitamiseksi
GB9915179D0 (en) 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
CA2387920C (en) 1999-10-22 2008-08-26 Orion Corporation A new use of levosimendan
FI20001542L (fi) * 2000-06-29 2001-12-30 Orion Yhtymae Oyj Menetelmä septisen sokin hoitamiseksi
FI20002525A7 (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Tulehduksenvastaisia aineita
FI20002526A7 (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Pyridatsinonijohdannaisten uusi käyttö
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
FI20010233A0 (fi) 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
JPWO2004087641A1 (ja) * 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) * 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
AU2005249498B2 (en) * 2004-05-28 2010-06-24 Orion Corporation Methods for treating a mammal before, during and after cardiac arrest
JP2008533109A (ja) 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
HUE033546T2 (hu) 2005-11-14 2017-12-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendán alkalmazása aszimptómás (rejtett) szívelégtelenség kezelésére
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008087248A1 (en) * 2007-01-17 2008-07-24 Orion Corporation Levosimendan for use in treating chronic valvular disease
CN102223882B (zh) 2008-11-25 2016-02-03 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
EP2454241B1 (en) 2009-07-14 2014-04-02 Cipla Limited Process for preparing levosimendan and intermediates for use in the process
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6511430B2 (ja) 2013-03-11 2019-05-15 ザ・ブロード・インスティテュート・インコーポレイテッド がんの治療のための化合物および組成物
EP3021832B9 (en) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN104418810A (zh) * 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 一种左西孟旦的合成新路线
CN103554032A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 高光学纯度(-)-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的制备方法
CN103554033A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 一种消旋体(±)- 6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的拆分方法
CA2930033C (en) 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
CA2995375C (en) 2015-08-13 2024-06-18 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3424908A1 (en) 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Process for preparation of levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
CN111548310B (zh) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型及其制备方法
CN111718299B (zh) * 2020-07-23 2023-03-10 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型b及其制备方法
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB228004A (en) * 1924-01-24 1925-01-29 Daimler Co Ltd Improvements in locking devices for sliding windows
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
GB8824458D0 (en) * 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile

Also Published As

Publication number Publication date
GEP19991868B (en) 1999-12-06
CA2099262A1 (en) 1992-07-04
EE02946B1 (et) 1996-12-16
JP3015748B2 (ja) 2000-03-06
JPH09183767A (ja) 1997-07-15
KR100207145B1 (ko) 1999-07-15
LU90920I2 (en) 2002-07-17
CY1878A (en) 1996-04-05
IE72101B1 (en) 1997-03-12
FI932618A0 (fi) 1993-06-09
EP0565546B1 (en) 1995-03-08
CA2099262C (en) 2002-03-12
ATE119525T1 (de) 1995-03-15
DE69201640D1 (de) 1995-04-13
AU645399B2 (en) 1994-01-13
EP0565546A1 (en) 1993-10-20
GB2251615A (en) 1992-07-15
CA2314115C (en) 2004-03-30
RO111847B1 (ro) 1997-02-28
GB9127145D0 (en) 1992-02-19
US5512571A (en) 1996-04-30
HU218659B (hu) 2000-10-28
YU200391A (sh) 1994-05-10
IL114028A0 (en) 1995-10-31
DK0565546T3 (da) 1995-05-22
JP2635445B2 (ja) 1997-07-30
PL169415B1 (pl) 1996-07-31
LV11174A (lv) 1996-04-20
HUT64754A (en) 1994-02-28
JPH06504275A (ja) 1994-05-19
IL100553A (en) 1995-12-31
NO2001021I1 (no) 2001-12-03
IL100553A0 (en) 1992-09-06
CA2314115A1 (en) 1992-07-04
FI105183B (fi) 2000-06-30
BG97915A (bg) 1994-04-29
HRP921251A2 (en) 1995-08-31
NO300682B1 (no) 1997-07-07
IL114028A (en) 1996-09-12
IE920002A1 (en) 1992-07-15
DE69201640T2 (de) 1995-08-10
BR1100737A (pt) 2000-03-21
HRP921251B1 (en) 2000-06-30
RU2118317C1 (ru) 1998-08-27
LV11174B (en) 1996-12-20
HU9301911D0 (en) 1993-09-28
HK117395A (en) 1995-07-28
US5569657A (en) 1996-10-29
FI932618L (fi) 1993-06-09
NZ241194A (en) 1993-06-25
YU48767B (sh) 1999-12-27
GB2251615B (en) 1995-02-08
BG62002B1 (bg) 1998-12-30
KR930703266A (ko) 1993-11-29
PL169435B1 (pl) 1996-07-31
NO932367L (no) 1993-06-28
WO1992012135A1 (en) 1992-07-23
SI9112003A (sl) 1998-10-31
NO932367D0 (no) 1993-06-28
US5424428A (en) 1995-06-13
AU1153592A (en) 1992-08-17

Similar Documents

Publication Publication Date Title
ES2070627T3 (es) Proceso para preparar (-)-((4-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridacinil)fenil)-hidrazono)propanodinitrilo.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
CY1106178T1 (el) 2’- υποκατεστημενα 1,1’-διφαινυλο-2-καρβοξαμιδια, μεθοδος για την παρασκευη τους, η χρηση τους ως φαρμακου καθως και φαρμακευτικα παρασκευασματα που τα πepιεχουν
DE69407785D1 (de) Benzoylbenzofuranderivate zur behandlung von herzarrhythmia
AU693261B2 (en) Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
RU94040170A (ru) Изохинолины
ATE72238T1 (de) Imidazoliumsalze, zwischenprodukte fuer ihre herstellung sowie ihre verwendung.
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
ATE207749T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung von atherosklerose und ischämischer herzerkrankungen
RU93004860A (ru) Гетероциклические соединения, способ их получения, использование и фармацевтическая композиция
ATE162076T1 (de) Verwendung von nadh und nadph zur herstellung eines arzneimittels zur behandlung von morbus alzheimer
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE136465T1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE3856052D1 (de) Anwendung des N-n-butyl-Derivates von Desoxynojirimycin zur Herstellung eines Arzneimittels zur Inhibierung von HIV-Virus
ATE214605T1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
DE60013876D1 (de) Nitroxyderivate von (r) und (s)-carnitin
EA199900363A1 (ru) Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
RU94045839A (ru) Производные 3-(фенилалкиламиноалкилокси)-5-фенилпиразола, а также способ и промежуточные вещества для их получения, лекарственное средство, содержащее эти соединения
SU648187A1 (ru) Состав дл консервировани роговиц человека
ES2080898T3 (es) Procedimiento para la preparacion de una ciclobutanona opticamente activa, un producto intermedio en la sintesis de un nucleosido de ciclobutano opticamente activo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 565546

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: REGISTRY NO/DATE: 64154 20010806, FIRST REGISTRY NO/DATE: FI15361 20000922

Filing date: 20020206